Skip to main content

Table 3 Survival of patients with t-AML based on age or period of diagnosis

From: Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia

  Median OS P value a 6-month OS 1-year OS 2-year OS 5-year OS
t-AML 1 month   25% 13% 6% 3%
Age   0.003     
 < 65 years 4 months   41% 22% 6% 2%
 ≥ 65 years < 1 month   11% 5% 5% 4%
Period of diagnosis   0.625     
 1975–1984 2 months   14% 14% 0% 0%
 1985–1994 < 1 month   25% 0% 0% 0%
 1995–2004 1 month   28% 14% 3% 3%
 2005–2015 1 month   25% 16% 9% 4%
  1. LC Lung cancer, t-AML Therapy-related acute myeloid leukaemia, OS Overall survival
  2. aThe P value is the median OS of t-AML patients based on age or period of diagnosis